Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06268873 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
A Phase 3 study of Chronic Kidney Disease and Hypertension, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 2,554
- Enrollment target
- 20
- Study locations
NCT06268873: Active Phase 3 study of Chronic Kidney Disease and Hypertension, sponsored by AstraZeneca.
NCT06268873 is a Phase 3 study of Chronic Kidney Disease and Hypertension that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 2,554 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (231% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06268873, a Phase 3 study of Chronic Kidney Disease and Hypertension, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,554 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants untreated with SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or placebo/dapagliflozin; and approximately 12-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin alone. Site visits will take place at 2-, 4-, 8-, and 16- weeks following randomisation. Thereafter visits will occur approximately every 4 months, until the 24-month visit at which time baxdrostat/placebo will be discontinued. Participants will continue open-label dapagliflozin for another 12-weeks (approximately), where reassessment of eGFR will occur for the primary efficacy endpoint. In the event of premature discontinuation of blinded study intervention, participants will continue in the study and receive open-label dapagliflozin monotherapy, unless the participant meets dapagliflozin specific discontinuation criteria, in which case all study interventions will be discontinued.
Primary Outcome
Change from baseline in eGFR to post treatment.
Conditions Studied
Interventions
- DRUG Baxdrostat/dapagliflozin
- DRUG Dapagliflozin in combination with placebo
Study Locations (20)
California
- Research Site - Beverly Hills
- Research Site - Canyon Country
- Research Site - Fremont
- Research Site - Fullerton
- Research Site - Lincoln
- Research Site - Los Alamitos
- Research Site - San Francisco
- Research Site - Stanford
- Research Site - Tarzana
Arizona
- Research Site - Phoenix
- Research Site - Surprise
- Research Site - Tucson
Florida
- Research Site - Boca Raton
- Research Site - Boynton Beach
- Research Site - Edgewater
Colorado
- Research Site - Arvada
- Research Site - Denver
Alabama
- Research Site - Fairhope
Arkansas
- Research Site - Searcy
Connecticut
- Research Site - New Britain
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,554 participants |
| Start Date | 2024-03-29 |
| Est. Completion | 2028-02-24 |
| Phase | Phase 3 |
What the registry record for NCT06268873 still lists
NCT06268873 is an interventional study that assigns participants to a tested intervention. Its 2,554 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (231% higher).
The record links to 1 condition, with Chronic Kidney Disease and Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Baxdrostat/dapagliflozin is the first listed.
NCT06268873 names 20 study sites across 7 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06268873 about?
NCT06268873 is a clinical study titled "A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.". The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants untreated with SGLT2i at baseline; a 24-month double-blind period...
What is the current status of trial NCT06268873?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,554 participants. The study started on 2024-03-29. Estimated completion is 2028-02-24.
What conditions does trial NCT06268873 study?
This clinical trial studies the following conditions: Chronic Kidney Disease and Hypertension.
What interventions are being tested in trial NCT06268873?
The interventions under investigation include: Baxdrostat/dapagliflozin (DRUG), Dapagliflozin in combination with placebo (DRUG).
Who is sponsoring clinical trial NCT06268873?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06268873 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease and Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06268873's enrollment target sits among peer trials
2,554 85th of 2000 higher than 1,916 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
RECRUITING · Phase 3
-
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05931276 · 2,540 participants · Phase 3
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
- NCT00018057 · 2,530 participants · Phase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- NCT04142177 · 2,529 participants · NA
Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI